抑制体细胞衰老促进诱导性多潜能干细胞（iPSC）生成的研究进展

doi:10.3864/j.issn.0578-1752.2015.16.015

摘要/Abstract

摘要： 诱导性多潜能干细胞（induced pluripotent stem cell, iPSC）是指对体细胞实施特定的诱导方法，将体细胞重编程获得的多潜能干细胞。最常用的诱导方法是利用基因导入技术，将与胚胎干细胞（embryonic stem cell, ESC）多潜能性相关基因的转录因子导入体细胞，激活内源多能性基因的表达，实现体细胞重编程。除转基因外，使用某些小分子物质或蛋白质等也可以实现体细胞重编程。iPSC与ESC在形态学、表观遗传学和分化能力上高度相似。由于iPSC来源于普通成体细胞，避免了胚胎干细胞面临的伦理道德和免疫排斥问题，使得这一技术在再生医学和畜牧生产上都具有广阔的应用前景。然而，iPSC的低生成率和高风险性逐渐成为制约该技术发展的主要障碍。生成效率和速率低，大大增加了获得iPSC的难度，工作量大且成本高；高风险性使iPSC无法安全应用于再生医学和生产转基因动物。这成为iPSC科研工作者亟待解决的两大问题。文章介绍了通过抑制体细胞衰老来促进iPSC生成的相关研究进展。该方法对体细胞重编程有显著效果，但同时也存在较大的安全性争议。控制细胞衰老凋亡的Ink4a/Arf位点，p53、pRB、p21等基因和蛋白因子可以及时清除体内损伤细胞，促进细胞衰老凋亡，抑制细胞癌变，组成了维护机体健康的重要调控通路。近年研究表明，抑制促细胞衰老凋亡基因的表达可显著提高iPSC生成的效率和速率，说明肿瘤发生和iPSC生成存在某些相同的调控通路。抑制体细胞衰老的方法主要有3类：改进培养液成分、使用新的转录因子和调节细胞培养环境。通过抑制体细胞衰老，最高可将小鼠iPSC生成效率提高到100%。这为高效获得iPSC，探索iPSC及肿瘤的生成机制提供了新思路。同时，此方法存在较大安全性问题。iPSC最初是由Oct4，Sox2，Klf4，c-Myc等4种转录因子诱导而来，这些因子本身都存在致癌风险。抑癌基因的失活使获得的iPSC致癌风险增大，成为制约该方法广泛应用的最主要障碍。文章概括了2008年以来通过抑制体细胞衰老促进iPSC生成的研究进展、存在问题和应用前景。

关键词: iPSC, 衰老, Ink4a/Arf, p53, 肿瘤

Abstract: Induced pluripotent stem cell (iPSC) refers to reprogrammed somatic cells with some specific induction methods. The most common induction method is transmitting embryonic stem cell (ESC)-related transfactors into somatic cell, to activate endogenous pluripotent genes. Up to now, except transgene technology, some small molecular substances or proteins can also realize somatic reprogram. iPSC is remarkably similar to ESC in morphology, epigenetics and differentiation ability. Because the resources of iPSC are ordinary somatic cells, iPSC technology avoids the defects of ESC in morals and immunological rejection. As a result, iPSC has an expansive prospect both in regenerative medicine and animal production. However, the existing problems like low efficiency and high risk are key barriers which limit its development. Low-efficiency greatly increases the difficulty to achieve enough iPSC, it’s time and cost-consuming. While the high-risk blocks its application in regenerative medicine and transgenic animal. These are two urgent problems in iPSC which need to be solved by researchers. A most efficient but also a high-risky method was described in this review-improving iPSC generation by restraining somatic cell senescence. This method can remarkably improve iPSC generation efficiency, while it’s also high-risk. The locus, genes and protein factors such as Ink4a/Arf, p53, pRB and p21 in charge of eliminating injured cells in body, promote cell senescence and apoptosis to prevent cancerization, which compose the important regulatory pathways in organism. Recent studies showed that silence of these genes and pathways can improve the efficiency and speed of iPSC generation, which means the generation of iPSC and tumor may use some common regulatory pathways. There are three category methods to restrain somatic cell senescence, including ameliorating iPSC culture media, employing new transgenes and regulating culture environment. Mouse iPSC generation efficiency even can be improved to 100% by this way. These results provide a new method in efficiently obtaining iPSC and researching the generation mechanism of iPSC and tumor. At the same time, this method has to face the serious security problems. iPSC is firstly reprogrammed by four canon transgenes, Oct4, Sox2, Klf4 and c-Myc, these are oncogenic transfactors in some degrees. The silence of cancer suppressor genes will improve the cancer risk of iPSC, which becomes the most serious barrier for clinical replication of this method. This paper given an outline of studies on restraining cell senescence to improve iPSC generation efficiency, including the research progress, existing defects solutions and application prospect.

Key words: iPSC, senescence, Ink4a/Arf, p53, tumor

魏如雪，郝海生，赵学明，杜卫华，朱化彬. 抑制体细胞衰老促进诱导性多潜能干细胞（iPSC）生成的研究进展[J]. 中国农业科学, 2015, 48(16): 3258-3265.

WEI Ru-xue, HAO Hai-sheng, ZHAO Xue-ming, DU Wei-hua, ZHU Hua-bin . Studies of Improved Efficiency of Induced Pluripotent Stem Cell Generation by Restraining Somatic Cell Senescence[J]. Scientia Agricultura Sinica, 2015, 48(16): 3258-3265.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: https://www.chinaagrisci.com/CN/10.3864/j.issn.0578-1752.2015.16.015

https://www.chinaagrisci.com/CN/Y2015/V48/I16/3258

参考文献

[1] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126: 663-676.

[2] Liu Y, Cheng H, Gao S, Lu X, He F, Hu L, Cheng T. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia, 2013, 28: 1071-1080.

[3] Merino H, Singla D K. Notch-1 mediated cardiac protection following embryonic and induced pluripotent stem cell transplantation in doxorubicin-induced heart failure. PloS One, 2014, 9(7): e101024.

[4] Bird M J, Needham K, Frazier A E, van Rooijen J, Leung J, Hough S, Dottori M. Functional characterization of friedreich ataxia iPS-derived neuronal progenitors and their integration in the adult brain. PloS One, 2014, 9(7): e101718.

[5] Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen T W, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biology, 2008, 6(10): e253.

[6] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 131(5): 861-872.

[7] Yu J, Vodyanik M A, Smuga-Otto K, Antosiewicz-Bourget J, Frane J L, Tian S, Thomson J A. Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007, 318(5858): 1917-1920.

[8] Ni A, Wu M J, Nakanishi Y, Chavala S H. Facile and efficient reprogramming of ciliary body epithelial cells into induced pluripotent stem cells. Stem Cells and Development, 2013, 22(18): 2543-2550.

[9] Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends in Cell Biology, 2001, 11(11): S27-S31.

[10] Petros A M, Olejniczak E T, Fesik S W. Structural biology of the Bcl-2 family of proteins. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2004, 1644(2): 83-94.

[11] Knudson A G. Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the USA, 1971, 68(4): 820-823.

[12] Tamrakar S, Rubin E, Ludlow J W. Role of pRB dephosphorylation in cell cycle regulation. Frontiers in Bioscience, 2000, 5(1): 121-137.

[13] Mali P, Ye Z, Hommond H H, Yu X, Lin J, Chen G, Zou J, Cheng L. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts.Stem Cells, 2008, 26(8): 1998-2005.

[14] Utikal J, Polo J M, Stadtfeld M, Maherali N, Kulalert W, Walsh R M, Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature, 2009, 460(7259): 1145-1148.

[15] Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature, 2009, 460(7259): 1136-1139.

[16] Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature, 2009, 460(7259): 1132-1135.

[17] Kawamura T, Suzuki J, Wang Y V, Menendez S, Morera L B, Raya A, Belmonte J C I. Linking the p53 tumour suppressor pathway to somatic cell reprogramming.Nature, 2009, 460(7259): 1140-1144.

[18] Marión R M, Strati K, Li H, Murga M, Blanco R, Ortega S, Blasco, M A. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature, 2009, 460(7259): 1149-1153.

[19] Esteban M A, Wang T, Qin B, Yang J, Qin D, Cai J, Pei D. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell, 2010, 6(1): 71-79.

[20] Wang T, Chen K, Zeng X, Yang J, Wu Y, Shi X, Pei D. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell, 2011, 9(6): 575-587.

[21] He J, Kallin E M, Tsukada Y, Zhang Y. The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15^Ink4b. Nature Structural & Molecular Biology, 2008, 15(11): 1169-1175.

[22] Dang L, Feric N T, Laschinger C, Chang W Y, Zhang B, Wood G A, Stanford W L, Radisic M. Inhibition of apoptosis in human induced pluripotent stem cells during expansion in a difined culture using angiopoietin-1 derived peptide QHREDGS. Biomaterials, 2014, 35(5):7786-7799.

[23] Chu Z, Niu B, Zhu H, He X, Bai C, Li G, Hua J. PRMT5 enhances generation of induced pluripotent stem cells from dairy goat embryonic fibroblasts via down‐regulation of p53. Cell Proliferation, 2015, 48(1): 29-38.

[24] Chen T, Shen L, Yu J, Wan H, Guo A, Chen J, Pei G. Rapamycin and other longevity‐promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell, 2011, 10(5): 908-911.

[25] Bao L, He L, Chen J, Wu Z, Liao J, Rao L, Xiao L. Reprogramming of ovine adult fibroblasts to pluripotency via drug-inducible expression of defined factors. Cell Research, 2011, 21(4): 600-608.

[26] Bodnar A G, Ouellette M, Frolkis M, Holt S E, Chiu C P, Morin G B, Wright W E. Extension of life-span by introduction of telomerase into normal human cells. Science, 1998, 279(5349): 349-352.

[27] Su R J, Baylink D J, Neises A, Kiroyan J B, Meng X, Payne K J, Zhang X B. Efficient generation of integration-free iPS cells from human adult peripheral blood using BCL-XL together with Yamanaka factors. PloS One, 2013, 8(5): e64496.

[28] Martins‐Taylor K, Xu R H. Concise review: genomic stability of human induced pluripotent stem cells. Stem Cells, 2012, 30(1): 22-27.

[29] Gabriel B, Sureau F, Casselyn M, Teissié J, Petit P X. Retroactive pathway involving mitochondria in electroloaded cytochrome induced apoptosis: Protective properties of Bcl-2 and Bcl-XL. Experimental Cell Research, 2003, 289(2): 195-210.

[30] Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll U M. p53 has a direct apoptogenic role at the mitochondria. Molecular Cell, 2003, 11(3): 577-590.

[31] Tamaoki N, Takahashi K, Aoki H, Iida K, Kawaguchi T, Hatakeyama D, Tezuka K I. The homeobox gene DLX4 promotes generation of human induced pluripotent stem cells. Scientific Reports, 2014 Dec 4;4:7283. doi: 10.1038/srep07283.

[32] Hasegawa Y, Tang D, Takahashi N, Hayashizaki Y, Forrest A R, Suzuki H. CCL2 enhances pluripotency of human induced pluripotent stem cells by activating hypoxia related genes. Scientific Reports, 2014 Jun 24;4:5228. doi: 10.1038/srep05228.

[33] Forristal C E, Wright K L, Hanley N A, Oreffo R O, Houghton F D. Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction, 2010, 139(1): 85-97.

[34] Mathieu J, Zhang Z, Nelson A, Lamba D A, Reh T A, Ware C, Ruohola‐Baker H. Hypoxia induces re‐entry of committed cells into pluripotency. Stem Cells, 2013, 31(9): 1737-1748.

[35] Banito A, Rashid S T, Acosta J C, Li S, Pereira C F, Geti I, Gil J. Senescence impairs successful reprogramming to pluripotent stem cells. Genes & Development, 2009, 23(18): 2134-2139.

[36] Dang C V, O’Donnell K A, Zeller K I, Nguyen T, Osthus R C, Li F. The c-Myc target gene network. Seminars in Cancer Biology, 2006, 16: 253-264.

[37] Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature Biotechnology, 2008, 26: 101-106.

[38] Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, Deng H. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science, 2013, 341(6146): 651-654.

[39] Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K.Induced pluripotent stem cells generated without viral integration. Science, 2008, 322(5903): 945-949.

[40] Soldner F, Hockemeyer D, Beard C, Gao Q, Bell G W, Cook E G., Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell, 2009, 136(5): 964-977.

[41] Kim D, Kim C H, Moon J I, Chung Y G, Chang M Y, Han B S, Kim K S. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell, 2009, 4(6): 472.

[42] Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, Cotsarelis G, Brown E J. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell, 2007, 1(1): 113-126.

[43] Smith Z D, Nachman I, Regev A, Meissner A. Dynamic single-cell imaging of direct reprogramming reveals an early specifying event. Nature Biotechnology, 2010, 28(5): 521-526.

[44] Milhavet O, Lemaitre J M. Senescent-derived pluripotent stem cells are able to redifferentiate into fully rejuvenated cells. Tumor Dormancy, Quiescence, and Senescence, 2014(2): 265-276.

[45] Choi Y J, Lin C P, Ho J J, He X, Okada N, Bu P, He L. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nature Cell Biology, 2011, 13(11): 1353-1360.

[46] Ji J, Sharma V, Qi S, Guarch M E, Zhao P, Luo Z, Batada N N. Antioxidant supplementation reduces genomic aberrations in human induced pluripotent stem cells. Stem Cell Reports, 2014, 2(1): 44-51.

[47] Mayshar Y, Ben-David U, Lavon N, Biancotti J C, Yakir B, Clark A T, Benvenisty N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell, 2010, 7(4): 521-531.

[48] Saito S, Lin Y C, Murayama Y, Hashimoto K, Yokoyama K K. Human amnion-derived cells as a reliable source of stem cells. Current Molecular Medicine, 2012, 12(10): 1340-1349.

[49] Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nature Reviews Cancer, 2011, 11(4): 268-277.